{"hands_on_practices": [{"introduction": "In precision oncology, the value of a diagnostic test is not absolute; it depends critically on the population in which it is used. This exercise explores how to quantify the real-world performance of sentinel lymph node biopsy (SLNB) for staging oral cancer. By applying fundamental principles of diagnostic statistics [@problem_id:4755983], you will calculate the Positive Predictive Value ($PPV$) and Negative Predictive Value ($NPV$), which are essential for making informed decisions about further treatment, such as elective neck dissection.", "problem": "A precision diagnostic is being evaluated to stage occult cervical lymph node metastasis in early-stage oral cavity squamous cell carcinoma, where the decision to perform elective neck dissection and to tailor adjuvant systemic therapy relies on accurate nodal status. The test is a sentinel lymph node biopsy (SLNB) enhanced with cytokeratin immunohistochemistry (IHC). In the clinically node-negative population under consideration, the prevalence of occult nodal metastasis is $0.20$. Validation data for the SLNB protocol show a sensitivity of $0.90$ and a specificity of $0.95$. Using only foundational definitions of sensitivity, specificity, and Bayesâ€™ theorem, first compute the positive predictive value (PPV) and negative predictive value (NPV) in this setting, expressing all probabilities as decimals. Next, apply these characteristics to a cohort of $100$ consecutive, otherwise similar patients and estimate the expected numbers of true positives, false positives, true negatives, and false negatives. Finally, report the total expected number of correct classifications in the cohort as your final answer. If any intermediate quantities do not simplify to exact integers, retain exact decimal or fractional values. The final reported count of correct classifications must be an exact integer.", "solution": "The problem is valid as it is scientifically grounded, well-posed, and all necessary information is provided.\n\nLet $D+$ be the event that a patient has occult nodal metastasis (disease is present), and $D-$ be the event that the patient does not have the disease. Let $T+$ be the event of a positive test result, and $T-$ be the event of a negative test result.\n\nThe given information can be stated in terms of conditional probabilities:\nThe prevalence of the disease is the prior probability of a patient having the disease:\n$$P(D+) = 0.20$$\nThe sensitivity of the test is the probability of a positive test given the disease is present:\n$$P(T+|D+) = 0.90$$\nThe specificity of the test is the probability of a negative test given the disease is absent:\n$$P(T-|D-) = 0.95$$\n\nFrom this information, we derive the complementary probabilities:\nThe probability of a patient not having the disease:\n$$P(D-) = 1 - P(D+) = 1 - 0.20 = 0.80$$\nThe false negative rate (the probability of a negative test given the disease is present):\n$$P(T-|D+) = 1 - P(T+|D+) = 1 - 0.90 = 0.10$$\nThe false positive rate (the probability of a positive test given the disease is absent):\n$$P(T+|D-) = 1 - P(T-|D-) = 1 - 0.95 = 0.05$$\n\nThe first task is to compute the positive predictive value (PPV) and the negative predictive value (NPV).\n\nThe PPV is the probability that a patient with a positive test result actually has the disease, denoted $P(D+|T+)$. We use Bayes' theorem:\n$$PPV = P(D+|T+) = \\frac{P(T+|D+) P(D+)}{P(T+)}$$\nTo calculate this, we first need the total probability of a positive test, $P(T+)$, which is found using the law of total probability:\n$$P(T+) = P(T+|D+)P(D+) + P(T+|D-)P(D-)$$\nSubstituting the known values:\n$$P(T+) = (0.90)(0.20) + (0.05)(0.80) = 0.18 + 0.04 = 0.22$$\nNow, we can compute the PPV:\n$$PPV = \\frac{0.18}{0.22} = \\frac{18}{22} = \\frac{9}{11} \\approx 0.8182$$\nSo, the positive predictive value is exactly $\\frac{9}{11}$, or approximately $0.8182$.\n\nThe NPV is the probability that a patient with a negative test result is actually disease-free, denoted $P(D-|T-)$. Using Bayes' theorem again:\n$$NPV = P(D-|T-) = \\frac{P(T-|D-) P(D-)}{P(T-)}$$\nFirst, we find the total probability of a negative test, $P(T-)$:\n$$P(T-) = P(T-|D+)P(D+) + P(T-|D-)P(D-)$$\nSubstituting the known values:\n$$P(T-) = (0.10)(0.20) + (0.95)(0.80) = 0.02 + 0.76 = 0.78$$\nAs a consistency check, $P(T+) + P(T-) = 0.22 + 0.78 = 1.00$.\nNow, we can compute the NPV:\n$$NPV = \\frac{0.76}{0.78} = \\frac{76}{78} = \\frac{38}{39} \\approx 0.9744$$\nSo, the negative predictive value is exactly $\\frac{38}{39}$, or approximately $0.9744$.\n\nThe second task is to apply these findings to a cohort of $N=100$ patients to find the expected number of true positives (TP), false positives (FP), true negatives (TN), and false negatives (FN).\n\nThe expected number of patients with the disease in the cohort is:\n$$N_{D+} = N \\times P(D+) = 100 \\times 0.20 = 20$$\nThe expected number of patients without the disease is:\n$$N_{D-} = N \\times P(D-) = 100 \\times 0.80 = 80$$\n\nWe can now calculate the expected counts for each category:\n-   Expected True Positives ($E[TP]$): Patients with the disease who test positive.\n$$E[TP] = N_{D+} \\times P(T+|D+) = 20 \\times 0.90 = 18$$\n-   Expected False Negatives ($E[FN]$): Patients with the disease who test negative.\n$$E[FN] = N_{D+} \\times P(T-|D+) = 20 \\times 0.10 = 2$$\n-   Expected True Negatives ($E[TN]$): Patients without the disease who test negative.\n$$E[TN] = N_{D-} \\times P(T-|D-) = 80 \\times 0.95 = 76$$\n-   Expected False Positives ($E[FP]$): Patients without the disease who test positive.\n$$E[FP] = N_{D-} \\times P(T+|D-) = 80 \\times 0.05 = 4$$\n\nThe final task is to report the total expected number of correct classifications. Correct classifications are the sum of true positives and true negatives.\n$$E[\\text{Correct Classifications}] = E[TP] + E[TN]$$\nSubstituting the calculated values:\n$$E[\\text{Correct Classifications}] = 18 + 76 = 94$$\nThe total expected number of correct classifications in the cohort of $100$ patients is $94$. This is an exact integer as required by the problem statement.", "answer": "$$\n\\boxed{94}\n$$", "id": "4755983"}, {"introduction": "The selection of targeted and immunotherapies is guided by specific molecular biomarkers. For patients with head and neck squamous cell carcinoma, the expression level of Programmed death-ligand 1 (PD-L1) is a crucial factor in determining eligibility for immunotherapy with checkpoint inhibitors like pembrolizumab. This practice provides direct experience in calculating the Combined Positive Score (CPS) [@problem_id:4755951], a standardized scoring system that translates immunohistochemical staining data into a clear-cut threshold for treatment decisions.", "problem": "An oral cavity squamous cell carcinoma, a subtype of Head and Neck Squamous Cell Carcinoma (HNSCC), is profiled for Programmed death-ligand 1 (PD-L1) expression by immunohistochemistry. Precision immunotherapy selection for the anti-Programmed cell death protein 1 (PD-1) antibody pembrolizumab in this setting is commonly guided by the Combined Positive Score (CPS), which by definition is the ratio of the number of PD-L1 staining cells (including tumor cells, lymphocytes, and macrophages) to the total number of viable tumor cells, scaled by a factor of $100$ to yield a unitless index. In a representative field curated to avoid necrotic areas and overlapping nuclei, there are $150$ PD-L1 staining cells and $1000$ viable tumor cells. Starting from the stated definitional ratio for CPS, derive the appropriate expression, compute the CPS, and determine whether the tumor meets an eligibility threshold of $\\mathrm{CPS} \\geq 10$ for pembrolizumab use in this disease context. Express your final answer as the numerical value of the Combined Positive Score (no units, no percentage sign). Do not round unless necessary.", "solution": "The problem is validated as scientifically grounded, well-posed, objective, and complete. All necessary information is provided to perform the required calculation and assessment. The context is a standard application of a biomarker in clinical oncology, and the provided definition and values are consistent with established practice.\n\nThe problem asks for the derivation and computation of the Combined Positive Score (CPS) and an assessment of eligibility for immunotherapy based on a given threshold.\n\nFirst, we formalize the definition of the CPS. Let $N_{\\text{PD-L1+}}$ represent the number of PD-L1 staining cells, which includes tumor cells, lymphocytes, and macrophages. Let $N_{\\text{tumor}}$ represent the total number of viable tumor cells. According to the problem statement, the CPS is defined as the ratio of these two quantities, scaled by a factor of $100$. The definitional equation is:\n$$ \\text{CPS} = \\frac{N_{\\text{PD-L1+}}}{N_{\\text{tumor}}} \\times 100 $$\nThis formula yields a unitless index, as specified.\n\nThe problem provides the following data from a representative field:\nThe number of PD-L1 staining cells, $N_{\\text{PD-L1+}} = 150$.\nThe total number of viable tumor cells, $N_{\\text{tumor}} = 1000$.\n\nWe substitute these values into the definitional equation for the CPS:\n$$ \\text{CPS} = \\frac{150}{1000} \\times 100 $$\n\nPerforming the division first:\n$$ \\frac{150}{1000} = 0.15 $$\n\nNow, multiplying by the scaling factor of $100$:\n$$ \\text{CPS} = 0.15 \\times 100 = 15 $$\nThe calculated Combined Positive Score is $15$.\n\nThe second part of the task is to determine if the tumor meets the eligibility threshold for pembrolizumab treatment in this context. The specified threshold is $\\text{CPS} \\geq 10$.\n\nWe compare our calculated CPS value to this threshold:\n$$ 15 \\geq 10 $$\nThis inequality is true. Therefore, the tumor meets the eligibility criterion for the administration of pembrolizumab.\n\nThe question asks for the numerical value of the Combined Positive Score as the final answer. The calculated value is $15$.", "answer": "$$\n\\boxed{15}\n$$", "id": "4755951"}, {"introduction": "Precision in therapy involves not only selecting the right agent but also delivering it effectively. For localized treatments like Photodynamic Therapy (PDT), this requires an understanding of the physics of energy delivery. This problem delves into the biophotonic principles of light dosimetry [@problem_id:4755961], where the therapeutic effect is dependent on delivering a sufficient light dose (fluence) to the tumor, a quantity that is attenuated as it penetrates tissue. Mastering these calculations is key to optimizing treatment plans for efficacy and safety.", "problem": "A patient with early-stage oral squamous cell carcinoma is planned for Photodynamic Therapy (PDT), using a continuous-wave red light source delivered through a flat-field fiber at the mucosal surface. The light source irradiates the tissue with an irradiance of $100$ mW per cm$^2$ for a continuous exposure of $300$ s. For homogeneous oral mucosa, assume that the spatial attenuation of the fluence rate into tissue can be modeled under the diffusion approximation by an exponential decay with an effective attenuation coefficient $\\mu_{\\text{eff}}$, so that the fluence (energy per unit area) at depth $z$ satisfies $D(z)=D(0)\\exp(-\\mu_{\\text{eff}} z)$, where $D(0)$ is the surface fluence delivered.\n\nStarting from the core definitions that irradiance is power per unit area and fluence (light dose) is energy per unit area, and using the well-tested exponential attenuation model with $\\mu_{\\text{eff}}=3$ cm$^{-1}$ for oral mucosa, derive an expression for the surface fluence $D(0)$ in J per cm$^2$ and the attenuated fluence at $z=2$ mm depth. Compute both values numerically.\n\nExpress the final answer in J per cm$^2$ and round to three significant figures. Provide both the surface fluence and the $2$ mm depth fluence in a single ordered pair.", "solution": "The problem is evaluated to be scientifically grounded, well-posed, and objective. It contains all necessary information and is free from contradictions or fallacies. The described scenario aligns with established principles of medical physics and biophotonics for Photodynamic Therapy (PDT). Thus, a full solution is warranted.\n\nThe problem requires the calculation of light fluence at the surface of oral mucosa and at a specified depth. We begin by establishing the relationship between the provided physical quantities.\n\nIrradiance, denoted by $I$, is defined as power $P$ per unit area $A$:\n$$I = \\frac{P}{A}$$\nThe units of irradiance provided are milliwatts per square centimeter ($\\text{mW}/\\text{cm}^2$).\n\nFluence, also known as light dose, denoted by $D$, is defined as the total energy $E$ delivered per unit area $A$:\n$$D = \\frac{E}{A}$$\nThe requested units for fluence are joules per square centimeter ($\\text{J}/\\text{cm}^2$).\n\nFor a continuous-wave light source delivering a constant power over a time interval $t$, the energy is related to power by $E = P \\times t$. By substituting this into the definition of fluence, we can relate fluence to irradiance:\n$$D = \\frac{P \\times t}{A} = \\left(\\frac{P}{A}\\right) \\times t = I \\times t$$\nThis equation allows us to calculate the fluence from the given irradiance and exposure time.\n\nFirst, we calculate the surface fluence, $D(0)$. The problem states the surface irradiance is $I = 100 \\text{ mW}/\\text{cm}^2$ and the exposure time is $t = 300 \\text{ s}$. To obtain the fluence in $\\text{J}/\\text{cm}^2$, we must first convert the irradiance units from $\\text{mW}/\\text{cm}^2$ to $\\text{W}/\\text{cm}^2$, and then use the identity $1 \\text{ W} = 1 \\text{ J}/\\text{s}$.\n$$I = 100 \\frac{\\text{mW}}{\\text{cm}^2} = 100 \\times 10^{-3} \\frac{\\text{W}}{\\text{cm}^2} = 0.1 \\frac{\\text{W}}{\\text{cm}^2}$$\nSince $1 \\text{ W} = 1 \\text{ J}/\\text{s}$, the irradiance is:\n$$I = 0.1 \\frac{\\text{J}}{\\text{s} \\cdot \\text{cm}^2}$$\nNow, we can calculate the surface fluence $D(0)$ by multiplying the irradiance by the exposure time:\n$$D(0) = I \\times t = \\left(0.1 \\frac{\\text{J}}{\\text{s} \\cdot \\text{cm}^2}\\right) \\times (300 \\text{ s}) = 30 \\frac{\\text{J}}{\\text{cm}^2}$$\n\nNext, we calculate the attenuated fluence at a depth of $z = 2 \\text{ mm}$. The problem provides an exponential decay model for the fluence as a function of depth $z$:\n$$D(z) = D(0) \\exp(-\\mu_{\\text{eff}} z)$$\nWe are given the effective attenuation coefficient $\\mu_{\\text{eff}} = 3 \\text{ cm}^{-1}$. The depth is $z = 2 \\text{ mm}$. For unit consistency in the exponent, we must convert the depth from millimeters to centimeters:\n$$z = 2 \\text{ mm} = 0.2 \\text{ cm}$$\nThe exponent is the dimensionless product $-\\mu_{\\text{eff}} z$:\n$$-\\mu_{\\text{eff}} z = -(3 \\text{ cm}^{-1}) \\times (0.2 \\text{ cm}) = -0.6$$\nSubstituting the known values into the attenuation model:\n$$D(z=0.2 \\text{ cm}) = D(0) \\exp(-0.6) = \\left(30 \\frac{\\text{J}}{\\text{cm}^2}\\right) \\exp(-0.6)$$\n\nFinally, we compute the numerical values and round them to three significant figures as requested.\nThe surface fluence is $D(0) = 30 \\text{ J}/\\text{cm}^2$. Expressed to three significant figures, this is $30.0 \\text{ J}/\\text{cm}^2$.\nFor the fluence at depth $z = 2 \\text{ mm}$:\n$$D(z=0.2 \\text{ cm}) = 30 \\times \\exp(-0.6) \\approx 30 \\times 0.5488116... \\approx 16.464348... \\frac{\\text{J}}{\\text{cm}^2}$$\nRounding this result to three significant figures yields:\n$$D(z=0.2 \\text{ cm}) \\approx 16.5 \\frac{\\text{J}}{\\text{cm}^2}$$\n\nThe final answer is the ordered pair of the surface fluence and the fluence at $2 \\text{ mm}$ depth, $(D(0), D(z=2 \\text{ mm}))$.\nThe resulting pair of values is $(30.0, 16.5)$, with units of $\\text{J}/\\text{cm}^2$.", "answer": "$$\n\\boxed{(30.0, 16.5)}\n$$", "id": "4755961"}]}